Rein Therapeutics, Inc. Write off of Deferred Debt Issuance Cost
Rein Therapeutics, Inc. (RNTX) reported Write off of Deferred Debt Issuance Cost of $1.50 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-04-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2018-04-02
- Rein Therapeutics, Inc. write off of deferred debt issuance cost for the quarter ending 2016-12-31 was $0.00.
- Rein Therapeutics, Inc. write off of deferred debt issuance cost for the quarter ending 2016-09-30 was $0.00.
- Rein Therapeutics, Inc. write off of deferred debt issuance cost for fiscal 2016 was $1.50M.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 6 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $0.00 derived: sum of 2 quarters · filed 2018-04-02 | $1.50M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.50M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $1.50M 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |